
Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
This trial is looking at 3 different drugs to have before surgery for kidney cancer. You have them either on their own or in combination.
It is open to people with a type of kidney cancer called clear cell renal cancer who can have surgery to remove it.
The standard treatment for kidney cancer is surgery to remove cancer in the kidney. This might be taking out the whole kidney (nephrectomy) or part of the kidney (partial nephrectomy). Sometimes people have further treatment with cancer drugs after their surgery. You usually don’t have cancer drugs before surgery.
In this trial you will have drugs before surgery. The drugs they are looking at target different parts of cancer cells and can reduce the size of the cancer. You would normally have these drugs for longer than you will in this trial. So the researchers don’t think they will make the cancer smaller. But they think it will give them important information about how they work on the cancer cells. This will help in testing these drugs in future clinical trials.
There are 3 drugs. Depending on when you join this trial you might get 1 of these drugs or a combination of them. The drugs are:
Cediranib is a cancer growth blocker called a tyrosine kinase inhibitor (TKI). It works by blocking the protein tyrosine kinase that cancer cells need to grow and multiply.
Durvalumab is an immunotherapy. It works by helping the body’s fight cancer.
Olaparib is a called a PARP inhibitor. PARP is a protein that helps damaged cells repair themselves. By blocking PARP cancer cells can’t repair themselves and so they die.
As a part of the trial you give samples of cancer tissue () and have
done.
The aim of this trial is to look at these tissue samples and scans to find out if these drugs or combination of drugs might work for kidney cancer.
The following bullet points list the entry conditions for this trial. Talk to your doctor or the trial team if you are unsure about any of these. They will be able to advise you.
Who can take part
You may be able to join this trial if all of the following apply. You:
Who can’t take part
You cannot join this trial if any of these apply.
Cancer related
You:
Medical conditions
You cannot join this trial if any of these apply.
Other
You cannot join this trial if any of these apply. You:
There are other reasons why you might not be able to have one of the treatments used in the trial.
Cediranib and olaparib
You cannot have cediranib or olaparib if any of the following apply. You:
Durvalumab
You cannot have durvalumab if any of the following apply. You:
This is a phase 2 trial. The team need up to 76 people to join.
You have treatment while you are waiting to have surgery. Depending on when you join the trial you might have one of the following:
Cediranib is a tablet. You take it once a day every day for at least 2 weeks till 36 hours (1½ days) before surgery.
Olaparib is a tablet. You take it twice a day every day for at least 2 weeks until the morning of surgery.
You have a diary to write down when you have your tablets and how many. You must bring this with you when you go to a hospital appointment.
You have durvalumab as a drip into a vein. You have it once at least 2 weeks before surgery. You have durvalumab at the hospital. It takes an hour to have.
Research samples
The research team take a small piece of tissue (biopsy) when you join the trial. This is to confirm that your kidney cancer is a clear cell renal cancer.
You give blood samples and urine samples:
Researchers use these samples to find:
MRI scan study
The team might ask you to have a scan called a hyperpolarised MRI scan. As part of the scan you have an injection of a. This can help the team see the cancer better and to find out how well treatment is working.
If you are having the hyperploarised MRI scan the team might ask to have another injection of the contrast fluid soon after the first.
By doing another injection and scan they want to show that the results of each are they same.
You don't have to agree to this. You can still take part in the trial.
You see the doctor to have tests before taking part. These tests include:
You see the doctor when you start treatment and 2 weeks later for:
After surgery you see the doctor at 6 weeks to see how you are and for:
You then see the doctor at 3 months for:
The trial team monitor you during treatment and afterwards. Contact your advice line or tell your doctor or nurse if any side effects are bad or not getting better.
Durvalumab can affect the immune system. It may cause inflammation in different parts of the body which can cause serious side effects. They could happen during treatment, or some months after treatment has finished. Rarely, these side effects could be life threatening.
If you have any of these side effects, you should tell the doctor or nurse as soon as possible that you are on or have been on an immunotherapy.
The most common side effects of durvalumab are:
The most common side effects of cediranib are:
The most common side effects of olaparib are:
Your doctor or a member of the trial team will talk to you about the possible side effects of the treatments before you agree to take part.
We have more information about:
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Grant Stewart
Cambridge University Foundation Hospital Trust
University of Cambridge
AstraZeneca
Cancer Research UK Cambridge Centre
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.